tno155
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
Novartis PharmaceuticalsPhase 1/2
—
Rating in progress
tno155 in Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC) is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Active